{% extends 'base.htm' %}
{% block title %}Case Studies | Pharma Data Associates, LLC{% endblock %}
{% block content %}

<p><strong>Case Studies</strong></p>

  <div class="content">
    <div id="node-6" class="node node-page node-promoted node-full clearfix">



  <div class="content clearfix">
    <div class="field field-name-body field-type-text-with-summary field-label-hidden"><div class="field-items"><div class="field-item even"><p><strong>Cost Savings as a Result of Sample Size Reduction</strong></p>

<ul>
	<li>Early termination of a phase 2b and extension trials using Bayesian posterior predictive probability - a 50% cost saving</li>
	<li>Sample size re-estimation using Bayesian posterior predictive probability - a 30% reduction in trial length</li>
</ul>

<p><strong>Rescue Mission for an NDA Submission</strong></p>

<ul>
	<li>NDA re-prepared with amended phase 3 CSRs, new ISS, new statistics data package compliant to the FDA eSubmission requirement - all completed in 2Â½ months</li>
</ul>

<p><strong>Consideration in Study Design</strong></p>

<ul>
	<li>Mid-course modification of a group sequential trial from the O'Brien-Flembing "spending function" to an ad hoc Lan-DeMets spending function</li>
	<li>Non-inferiority study design for a cardiovascular drug with MACE endpoint - a sample size challenge</li>
</ul>


{% endblock %}

{% block footer %}{% endblock %}
